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Abstract 
Studies in several tumour sites highlight the significance of the CpG island 
methylation phenotype (CIMP), with distinct features of histology, biological 
aggression and outcome.  We utilise pyrosequencing techniques of quantitative 
methylation analysis to investigate the presence of CIMP in oral squamous cell 
carcinoma (OSCC) for the first time, and evaluate its correlation with allelic 
imbalance, pathology and clinical behaviour. Tumour tissue, control tissue and 
PBLs were obtained from 74 patients with oral squamous cell carcinoma. 
Pyrosequencing was used to analyse methylation patterns in 75–200 bp regions 
of the CpG rich gene promoters of 10 genes with a broad range of cellular 
functions. Allelic imbalance was investigated using a multiplexed panel of 11 
microsatellite markers. Corresponding variables, histopathological staging and 
grading were correlated with these genetic and epigenetic aberrations. A cluster 
of tumours with a greater degree of promoter methylation than would be  
predicted by chance alone (P = 0.001) were designated CIMP+ve. This group 
had less aggressive tumour biology in terms of tumour thickness (p = 0.015) and 
nodal metastasis (P = 0.012), this being apparently independent of tumour 
diameter. Further, it seems that these CIMP+ve tumours excited a greater host 
inflammatory response (P = 0.019). The exact mechanisms underlying CIMP 
remain obscure but the association with a greater inflammatory host response 
supports existing theories relating these features in other tumour sites. As CIMP 
has significant associations with other well documented prognostic indicators, it 
may prove beneficial to include methylation analyses in molecular risk modelling 
of tumours.
Introduction 
 
Increasing interest in cancer epigenetics has been reflected in the head and neck 
cancer literature1-3.  It is now beyond dispute that aberrant cytosine methylation 
within CpG islands of tumour suppressor gene promoter regions4 is critical to 
cancer development, and in particular, the earlier stages. This is not to suggest a 
diminished role of genetic changes such as deletion or mutation. Indeed it is 
suggested, in a modification of Knudson‟s double hit hypothesis4;5, that in some 
circumstances one allele of a tumour suppressor gene may be inactivated by 
methylation and the other by genetic means. As with other fields of molecular 
biology, increasing knowledge is precipitated by technological advances. In 
epigenetics, the roles of bisulphite modification6, methylation dependent 
restriction enzymes7, real-time PCR8, pyrosequencing9;10 and various array 
techniques11 have meant that DNA methylation is now one of the better 
characterised of molecular abnormalities in cancer. 
 
Evidence suggests that the distribution of methylation at various gene promoters 
across a tumour series follows identifiable patterns.  Tumours that have 
methylation at one gene are more likely to have other sites of methylation. This 
has been described as concordant methylation and the CpG island methylation 
phenotype (CIMP) and was first described 1999 in colorectal cancer12, and 
shortly after in gastric cancer13. There was also a distinct tumour morphology and 
behaviour associated with highly methylated tumours (“CIMP high”).  This 
concept mirrored in the epigenetic field what had been a long accepted genetic 
concept in colorectal cancer, i.e. microsatellite instability (MSI). In MSI mediated 
tumours, a defect in DNA repair leads to high rates of mutation and the selection 
of clones with growth advantage leading to the development of a malignant 
tumours14. The concept of these selective processes existing in the epigenetic 
field, however, has not been universally accepted by the scientific community15. 
The issue was further clouded by the linking of these two phenomena after the 
discovery that promoter methylation of the mismatch repair gene MLH1 was 
implicated in MSI14.  A search of the literature fails to throw any light on the 
initiating factor in CIMP, analogous to MLH1 down-regulation in MSI, although 
work has understandably focussed on the DNA methyl-transferase mechanism16. 
 
Subsequent work in various tumour sites has confirmed the presence of CIMP in 
T cell leukaemia17, hepatocellular carcinoma18, neuroblastoma19 as well as 
gastric and colorectal adenocarcinoma. In a recent large study, Samowitz20 
evaluated the CIMP and MSI concepts in colorectal adenocarcinoma.  They 
found that CIMP was associated with mutations of BRAF and KRAS2, older age, 
increased stage and poorer prognosis and showed a trend with mucinous 
histology. In addition, they also found that MSI has a major effect on phenotype, 
in effect describing four categories of tumour defined by CIMP-high/low and MSI-
high/low. Recent work in colorectal cancer even suggests a different 
pathogenesis in right and left sided tumours that correlates with the presence of 
CIMP21, while in gastric cancers, CIMP has been associated with EBV DNA 
positivity22;23. There has also  been some speculation that CIMP represents a 
molecular signature consistent with inflammation mediated neoplasia across a 
variety of tumour sites24 and it would also seem logical that sensitivity to 
epigenetic therapy may be profoundly linked to CIMP. 
 
There are, as yet, neither published accounts of CIMP, nor any phenotypic or 
prognostic associations in head and neck squamous cell cancer (HNSCC).  
Various accounts have classified the pattern of methylation over several 
genes25;26 or the global methylated cytosine “load” found in the whole genome27 
in HNSCC, but the investigation of the CIMP phenomenon in HNSCC is overdue, 
particularly as the most conclusive evidence stems from other regions of the 
aerodigestive tract. Whilst MSI appears to be rather rare in HNSCC, it might be 
informative to instead examine any relationship between allelic imbalance at key 
loci with CIMP. 
 
 We are convinced by the argument that quantitative methylation analysis offers 
convincing benefits in the accurate identification of CIMP28 and aimed to use 
pyrosequencing methods to investigate a consecutive HNSCC series.  The 
pattern of allelic imbalance at chromosomal regions implicated in HNSCC was 
also defined using a panel of microsatellite markers in order to ascertain and 
correlate the genetic contribution in the same tumour series. These epigenetic 
and genetic aberrations were then compared with histopathological parameters 
and clinical outcome data in order to clarify whether the CIMP concept has 
validity in HNSCC. 
 
Methods 
 
Patient cohort and tissue procurement 
 
74 patients presenting to a head and neck cancer regional referral unit were 
selected for this study. The selection criteria included biopsy proven oral or oro-
pharyngeal squamous cell carcinoma (ICD-O C02 –C09), an intention to treat by 
primary surgery and the absence of previous similar malignancy or treatment. 
5mm3 tumour and “normal” margin samples were taken during surgery and snap 
frozen in liquid N2. 5ml venous blood was collected into EDTA and centrifuged at 
2000 x g for 5 minutes.  Plasma was drawn off and the cell pellet was snap 
frozen.  All samples were subsequently stored at–85oC until DNA preparation. 
Detailed tumour and patient characteristics were documented, including clinical 
and pathological TNM grading. The commonest tumour sub-sites included 
anterior floor of mouth (C04) 20 (27%), tongue (C02.0,C02.2) 17 (23%) and tonsil 
(C09.0,C09.1,C09.9) 7 (10%) . pTNM pathological grading subsequent to 
resection was: pT1: 14 (19%); pT2: 30 (41%); pT3: 7 (9%); pT4: 23 (31%). 29 
cases (39%) were pN positive and 18 (24%) had extra-capsular spread.  
Sample preparation 
DNA was extracted from the 2mm3 frozen tissue and white cell samples using a 
DNeasy™ tissue kit (Qiagen Ltd). Both tumour and “normal” margin tissues were 
prepared in parallel for methylation analysis. Bisulphite treatment of 2µg of each 
sample (for use in methylation assays) was undertaken using the EZ DNA 
Methylation Kit™ (Zymo Research) and the converted DNA eluted in 50µl of 0.1 X 
TE buffer.   
 
Selection of genes for methylation assay 
 
By combining review of the existing literature with our recently generated 
experimental data, a panel of 10 genes was formulated and appropriate primers 
were designed to amplify CpG islands within their promoter regions. p16 is the 
most commonly studied gene down regulated by promoter methylation2 and is 
involved in cell cycle checkpoint control. Another cell cycle control gene, cyclin 
A1, was recently identified by a pharmacological unmasking array approach29 
and has since been validated by pyrosequencing in OSCC9. The DNA repair 
mechanisms are represented by ATM30, hMLH131 and MGMT32, all of which have 
been suggested to be controlled by epigenetic means. There is a relatively 
extensive literature describing promoter methylation of cell differentiation 
regulation gene RARβ33;34 and the cell adhesion molecule E-cadherin35. In 
contrast, only recently has this mechanism been suggested in the cell signaling 
molecule STAT136 and the matrix metalloproteinase inhibitor TIMP337. Cytoglobin 
is a gene of unknown function that has been identified as a candidate tumour 
suppressor gene from our research group‟s recent work on tylosis, an inherited 
cancer syndrome38-41.  Its downregulation by promoter hypermethylation has 
been recently demonstrated in upper aerodigestive tract squamous carcinoma 
including HNSCC39.   
Quantitative pyrosequencing methylation analysis (PMA) 
PMA was carried out as previously described9. Briefly, hot start PCR was carried 
out using 3µl of bisulphite treated DNA template in each reaction. Primer 
sequences, PCR conditions and pyrosequencing primer sequences are available 
on request.  Confirmation of PCR product quality and freedom from 
contamination was established on 2% agarose gels with ethidium bromide 
staining. Pyrosequencing was carried out using the PSQ96MA System 
(Biotage™) according to manufacturer‟s protocol, including single strand binding 
protein (PyroGold™ reagents). An average methylation index (MtI) was 
calculated from the mean of the CpG sites evaluated (between 4 and 20 CpG 
dinucleotides per promoter per sample) as previously described39.  
 
Multiplex microsatellite analysis of allelic imbalance 
 
A multiplexed panel of microsatellite markers was used as described before41-43. 
Briefly, PCR primers for the microsatellite loci D3S1263, D3S1289, D3S1300, 
D3S1566, D5S644, D9S157, D9S161, D13S153, D13S171, D13S263, and 
D17S938 were selected from Applied Biosystems linkage sets. These markers 
have previously been shown to show consistent allelic imbalance in 
aerodigestive tract squamous carcinoma samples42. Forward primers had 5' 
fluorescent modification and the reverse primers had a 5' biotin modification. 
Multiplex PCR reactions (10 µl) contained 2 µl  (0.2 µg) of genomic (non-
bisulphite treated) DNA from tumour or blood cells, 1µl relevant primers, 5 µl  of 
Qiagen Multiplex PCR Kit Master Mix and 2 µl dH2O. Cycling conditions were 
95°C for 15 min, 30 cycles (94°C for 30 s, 56°C for 90 s, 72°C for 60 s) followed 
by 30 min at 60°C. PCR products were purified using 2 µl Dynabeads M-280 
Streptavidin and resuspended in 4 µl of loading buffer (10:2:1 formamide, dextran 
blue/EDTA, ROX 400HD size standard). Samples were denatured at 95°C for 5 
min, chilled on ice and 1 µl was loaded on a 5% denaturing polyacrylamide gel 
on a 377 ABI™ sequencer. The gel image was analysed using the ABI 
Genescan™ and Genotyper™ software.  
 
Allelic imbalance was scored according to previously established performance 
criteria41 and was present if the allelic ratio (A1/A2 tumour)/(A1/A2 leukocyte) 
was outside a range of 1.25-0.75. Assays were carried out in duplicate and AI 
scored only if both results for an individual sample were outside the normal 
range.  A chromosomal arm was recorded as showing allelic imbalance if any 
one of the corresponding informative (heterogeneous) microsatellite markers 
showed a loss. Fractional allelic loss (FAL) was also calculated for each tumour, 
representing the proportion of informative chromosomal arms that demonstrated 
loss. 
 
Detailed characterisation of histopathological features 
 
The 13 tumours with highest or lowest overall methylation status (as defined 
below) were selected. H&E stained histopathological slides were submitted for 
further detailed analysis by two experienced oral pathologists (GH & JAW). In 
total 22 tumours were available for analysis (12/13 high and 10/13 low). The 4 
other cases were rejected because either their tumours were principally intra-
osseous, missing, or otherwise unsuited for comparison. The pathologists were 
blinded to the methylation status. The morphology and architecture of each 
tumour was classified according to Anneroth & Hansen44  including assessment 
of the invasive front, nuclear polymorphism mitotic rate, degree of keratinisation 
and inflammatory response. Thus a range of scores for each component and 
total score of biological aggression was obtained for this subset of 22 tumours. 
 
Statistical Analysis 
 
The methylation index (MtI) for the tumour samples were normalised and 
subdivided into three groups (unmethylated, weakly and strongly methylated) in 
order to allow meaningful comparison between individual gene promoters. This 
was undertaken because the source tissue was not microdissected and 
consequently the MtI values for each sample were considered to more precise 
than accurate. The lower threshold, separating the unmethylated from the weakly 
methylated group, was derived as previously described9 by identifying the MtI 
that best separated the tumours from normal controls.. For the genes not 
displaying tumour specific promoter methylation, an arbitrary MtI value of 5% was 
used, which is consistent with our previous approach in considering the upper 
level of background noise generated during pyrosequencing9.   
 
The tumour samples with MtI below the lower threshold MtI were considered to 
be essentially unmethylated. The methylated samples were then divided using a 
median split into a “weakly methylated” group (MtI>lower threshold but <median 
value) and a “strongly methylated” group (MtI>median value). Each tumour 
sample was classified separately for each of the ten gene promoters considered.  
The threshold between strongly and weakly methylated samples was quite 
consistent at around MtI 0.25 ± 0.05 for each gene. Further corroboration for this 
approach arises from the (unpublished) observation that an MtIP 0.20–0.25 in 
these samples was necessary to silence mRNA expression for the corresponding 
gene. Additionally an aggregate methylation score was calculated for each 
tumour by adding the number of gene promoters with strong methylation. 
 
Correlations were made between the methylation status, allelic imbalance, 
pathological and clinical data available using SPSS software. For statistical 
calculations using aggregated measures of methylation scores or fractional allelic 
loss, a level of significance of p<0.05 was used. In considering the much larger 
number of correlations made between individual gene promoters and 
microsatellite markers, a more stringent level of P<0.01 was used.  
Results 
 
The percentages of unmethylated, weakly and strongly methylated tumours are 
illustrated for each gene in Table 1. The promoters of genes ATM, STAT1 and 
hMLH1 were methylated at less than 5% in all samples analysed and excluded 
from all further calculations. 
 
Concordant methylation 
 
In order to discover whether high methylation levels were occurring in an 
interrelated way (“concordant”) or merely as random events, a goodness of fit 
calculation of observed versus expected methylation was performed (Table 2). 
As an illustration, if methylation had occurred as a random, non-interrelated 
process, it would be expected that the number of tumours with 3 or more of the 7 
genes showing high methylation would be 5.7 however the actual count was 14. 
It was seen that the observed degree of methylation was greater than expected 
at both ends of the distribution. The overall goodness of fit indicated that 
promoter methylation occurred in a highly significantly interdependent or 
concordant manner (P<0.001).  The fourteen tumours with high MtI at several of 
the gene promoters seemed to form a distinct cluster and will be referred to as 
CIMP+ve tumours below. 
 
Further correlation between individual gene promoters was made (Table 3). It 
was seen that significant correlations existed between cytoglobin and RARb 
(Spearman correlation = 0.46, P < 0.01), cyclin A1 and MGMT (Spearman 
correlation = 0.35, P < 0.01). 
 
Correlation of methylation phenotype with allelic imbalance 
 
High levels of fractional allele loss (FAL), calculated from data at all 11 
microsatellites, were observed in strongly methylated tumours (Spearman 
correlation 0.25, P = 0.031).  Further exploration of correlations between 
individual chromosomal arms and individual gene promoters highlighted two 
noteworthy associations. Loss at 17p (D17S938) correlated with strong 
methylation at p16 (P=0.001 Pearson chi squared) and at cyclin A1 (P=0.010).  
Eight of 25 (32%) cases with allelic imbalance at D17S938 were strongly 
methylated at the p16 promoter and 6/24 (25%) at cyclinA1. By comparison, of 
those cases informative for D17S938 but without allelic imbalance, strong 
methylation was seen in 0/29 (0%) and 2/29 (7%) at p16 and cyclin A1, 
respectively.  No other significant correlations were apparent between promoter 
methylation and allelic imbalance (at either P < 0.05 or P < 0.01 level). 
 
Correlation of methylation phenotype with clinical features and outcome 
 
When considering the association of promoter methylation with clinico-
pathological parameters, there were significant associations between CIMP+ve 
cases and shallower tumour depth (P=0.015) and lower pN stage (P=0.012).  
Weak trends showing a lower incidence of extra-capsular nodal involvement 
(P=0.100 chi squared) and improved disease specific survival at 24 months 
(P=0.156) were also observed with CIMP+ve tumours.  It also seemed that there 
was less likely to be a premalignant lesion co-existent with the index tumour in 
CIMP+ve cases (P=0.084).  There were however, no significant correlations of 
CIMP status with gender, age, smoking, alcohol consumption, tumour sub-site, 
pT stage, mandibular invasion, or tumour involvement of surgical margins.  
 
Taken overall, a case builds that the CIMP+ve cases had less aggressive tumour 
biology. The significant correlations seem perhaps more notable as they were in 
keeping with the Anneroth score data presented below, and further, were 
independent of any relationship with tumour stage.  
 
Correlation of methylation phenotype with histopathological features 
 
The individual components within, and total sum of, Anneroth scores were 
compared between 12/14 CIMP+ve and 10 CIMP-ve cases as shown in Table 4. 
Whilst there was a trend (P=0.134 Mann-Whitney) between the CIMP-ve tumours 
and a higher overall Anneroth score (more aggressive), this was largely 
explained by an association between methylation and the inflammatory 
response. The CIMP+ve group had much greater inflammatory response in 
tissue at the deep margin adjacent to the tumour than the CIMP-ve group 
(P=0.019). This is further illustrated by figure 1.  
Discussion 
 
We have brought together genetic, epigenetic, histopathological and clinical data 
in a series of 74 oral squamous cell carcinoma cases to investigate the 
importance of promoter methylation on tumour behaviour.  We have found that 
there is a cluster of 14 tumours with a greater degree of promoter methylation 
than would be predicted by chance (P=0.001) and we adopt the term CIMP+ve to 
identify this group.  The CIMP+ve group have less aggressive tumour biology in 
terms of tumour thickness (p=0.015) and pathological nodal invasion (p=0.012), 
this being apparently being independent of tumour diameter.  Further, it seems 
that these CIMP+ve tumours excite a greater host inflammatory response 
(P=0.019) which might conceivably be related to this difference in clinical 
behaviour.   
 
This study has the advantage of combining data from several disciplines relevant 
to cancer biology. We have previously published a subgroup of the 
pyrosequencing derived methylation data analysed in this paper9 but the value of 
this quantitative approach is further highlighted in our current analysis of the 
methylation phenotype.  We have categorised the status of these tumour 
samples as unmethylated (or within the threshold for normal tissue or 
experimental error), weakly, or strongly methylated and have observed a number 
of possible clinically relevant associations. It seems clear that a tumour with 1% 
promoter methylation of a given gene might be expected to show a biologically 
significant difference of expression of the gene compared with another tumour 
with 50% methylation and that this difference would not be apparent using a non-
quantitative approach for detecting gene promoter methylation. We remain 
convinced that the pyrosequencing methylation assays described, whilst not the 
only quantitative method available, represent progress over simpler methods 
such as methylation specific PCR.  We also have the benefit of a multiplexed 
panel of microsatellite markers which has previously been rigorously validated 
and optimised in similar studies in aerodigestive tract malignancy41.  The 
inclusion of data from both routine post-operative pathological staging and from 
further focused examination of specimens has been essential, as has the clinical 
data derived from the Regional Maxillofacial Unit‟s head and neck database45. 
 
The number of gene promoters & microsatellites markers used in this study might 
be considered limited and could perhaps be usefully extended.  In particular, 
there are several other genes2 thought to be epigenetically silenced in OSCC 
such as DAPkinase, RASSF1, and DCC2. However, in this study we have 
attempted to incorporate a wide range of cellular functions within our panel and 
clearly these techniques are expensive in terms of logistics and in demand for 
high quality bisulphite treated DNA. A number of differing approaches are 
currently being considered in the development of a promoter methylation micro-
array11.  This has obvious attractions in the context of a study of CIMP, however 
they are not yet commercially available and it remains to be proven if they are 
sufficiently quantitative for this purpose. We also recognise that if the samples 
had been microdissected, there might have been differences in the results 
obtained.  In particular we have evidence that much higher levels of methylation 
might be detected in pure tumour tissue compared with non-microdissected 
specimens (unpublished).  There are, however, some drawbacks to this 
technique. Firstly the total quantity of DNA obtained is much smaller and, as has 
been commented above, these techniques demand relatively high quantity and 
quality of DNA, particularly as the bisulphite treatment essential to the assay 
causes a degree of fragmentation. Secondly, the use of microdissection adds 
significant logistical burden that might result in fewer cases being included in any 
study. 
 
The clear association that we observed between allelic imbalance at a locus 
close to p53 (D17S938) and methylation of the two cell cycle control genes 
studied (p16 and cyclin A1) is previously unreported.  We speculate that 
aberrations in cell cycle control will lead to higher cell turnover and consequently 
predispose to further aberrations.  It is difficult to know, assuming causation 
exists, which is the primary and which is the secondary event, although a recent 
paper by Maley et al46 propose that p16 inactivation (including by methylation) is 
the first event in the development of premalignant Barrett‟s oesophagus with p53 
inactivation developing later.  It would certainly be of interest to investigate other 
head and neck tumour series, and other sites, to see if this relationship is 
duplicated. 
 
A striking difference between the CIMP+ve and -ve cases was the host 
inflammatory response to the tumours seen on routine histopathology adjacent to 
the leading edge of the tumour. Whilst this response is usually taken as a 
favourable prognostic feature and may explain the correlation between CIMP+ve 
tumours and less aggressive tumour characteristics, there is also growing 
evidence that inflammation may have a role in carcinogenesis47. Clearly a 
distinction must be made between the inflammatory response to the tumour that 
we report here and any relationship to an inflammatory mechanism of 
pathogenesis.  However, an association between CIMP+ve tumours and 
inflammation is also described in research on several other tumour sites. It is 
thought that in some circumstances, chronic inflammation or hyperplasia 
becomes complicated by an abnormal epigenetic programme. This  then 
becomes „locked in‟, pre-disposing that clone to ultimate malignant 
transformation48. In gallbladder49 and colon cancer, the development of CIMP+ve 
tumours secondary to chronic inflammation have been described50 and a similar 
association between chronic inflammation and viral aetiology has been 
discovered in liver cancer51. The parallel finding that CIMP+ve gastric tumours 
had greater evidence of previous EBV infection52 allows speculation as to the 
viral aetiology of the methylation phenotype, which might also be pertinent to 
head and neck cancer. The work of Kang et al clarify the role of chronic 
inflammation and viral aetiology in both malignant and non-malignant gastric 
lesions which display CIMP53;54 while  Issa comments that the genes responsible 
for the creation of CIMP+ve tumours may not be in direct control of methylation, 
but perhaps be involved in the predisposition to exaggerated and chronic 
inflammation to certain stimuli24. Further work is required in oral squamous 
carcinoma to determine if HPV, EBV or other inflammatory triggers might 
predispose to CIMP+ve tumours. Another credible hypothesis might be 
pathogenesis relating to chronic premalignant conditions, for example, oral lichen 
planus. However our data argues against this, with a trend for CIMP+ve actually 
less likely (P = 0.084, NS) to be seen concurrent with premalignant conditions. 
 
Comparing our data on the CIMP in oral squamous carcinoma with other 
previously described sites, it is perhaps not unexpected that we have found 
correlations between the CIMP and histological subtype and also clinical 
behaviour. However we have not found any sub-site differences, in contrast to 
the predilection for the CIMP in certain areas of the bowel in colorectal 
adenocarcinoma.  Also, in contrast to much of the work on other sites, we have 
found that the CIMP+ve cases appeared to have tumours with more biologically 
favourable characteristics, although one recent study in gastric adenocarcinoma 
also found that CIMP+ve tumours had better prognosis55. The trend that we have 
identified towards improved disease specific survival did not reach statistical 
significance. However the finding of greater lymph node involvement and tumour 
thickness in CIMP-ve cases would routinely have triggered the prescription of 
post-operative radiotherapy or chemo-radiotherapy56 and this may have 
obscured at least some of the survival effects. Clearly the histology, aetiology 
and pathogenesis of oral squamous malignancy contrasts greatly with that of 
bowel or haematological malignancy and it is perhaps not surprising that such 
contrasts were found with previously published studies. It would be of interest to 
see if our findings were replicated in studies of laryngeal or other aerodigestive 
tract epithelial malignancy. 
 
In reviewing the results of this study, it is apparent that several themes for further 
research emerge, as well as implications for translational approaches.  The 
genes investigated covered a broad range of cellular functions including cell 
cycle control, DNA repair, cell adhesion, differentiation, signal transduction and 
response to hypoxia. Clearly, the demonstrated association between methylation 
of these genes would not seem to be directly causal, i.e. methylation of MGMT 
does not directly cause methylation of cyclinA1. These associations presumably 
result from some underlying alteration in DNA methyltransferase activity, the 
investigation of which might be of considerable value in understanding the 
malignant process. Whether this abnormality has a genetic or environmental 
aetiology is also of interest. A highly active focus for current translational 
research is epigenetic therapy i.e. using histone deacetylase inhibitors or 
manipulating DNA methyltransferase using 5-azacytidine to reverse epigenetic 
silencing of tumour suppressor genes. It is not known whether CIMP+ve tumours 
are more sensitive to such epigenetic therapy. If this was the case, it would be 
paradoxical that this novel approach used in oral squamous cell carcinoma would 
be more effective in the less aggressive tumours.  Another clinical exploitation of 
DNA methylation is the field of biomarkers i.e. to monitor DNA methylation in 
plasma, saliva or surgical margins to aid diagnosis or staging of disease. 
Similarly, the finding that methylation seems to be concentrated in less 
aggressive tumours perhaps may impose a restriction on the clinical translation 
of epigenetic biomarkers. 
 
HNSCC is often treated using primary surgery with adjuvant chemo- and 
radiotherapy being prescribed on the basis of pathological staging of the 
resected specimen. In particular, tumour thickness54 and the presence of cervical 
lymph node metastases55 are frequently cited as important criteria for 
radiotherapy. As CIMP has demonstrated associations with these prognostic 
indicators, it is possible that methylation analysis might form a useful component 
of risk modelling in future strategies of molecular grading. As the role of organ 
preservation in HNSCC expands, a relatively non-invasive assessment of tumour 
grading may also be useful. The CIMP+ve cases demonstrated a greater 
inflammatory reaction and this might shed new light on the host response to 
the tumour with its possible influence on outcome. 
 
The authors are unaware of any previous attempts to describe the CpG island 
methylation phenotype in head and neck cancer. We have taken a 
multidisciplinary approach, bringing together clinical pathological staging and 
outcome data with analysis of both genetic and epigenetic aberrations.  
Quantitative methylation analysis seems to offer significant advantages to the 
field and, using this approach, we have demonstrated several novel findings and 
associations.  These shed new light onto the role of methylation in 
carcinogenesis and offer new directions for further research. 
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  P16 CYCA1 MGMT ECAD TIMP3 RARβ CYGB 
Unmethylated 
 
73 44 71 59 97 27 57 
Weakly 
Methylated 
14 40 15 21 0 45 27 
Strongly 
Methylated 
14 15 14 20 3 28 16 
 
Table 1: Percentage of tumours showing promoter methylation 
N=74
 Count of 
“strongly 
methylated 
“promoters 
Observed (O)  
Expected (E) count  
(assuming independence of 
‟strong‟ methylation between 
genes) 
O vs E 
(O-E)
2
/E 
0 34 21.8 6.8 
1 19 29.9 3.9 
2 7 16.6 5.6 
3 10 4.9 5.3 
4 4 
0.8 12.8 
5 0 
6 0 
7 0 
Sum 74 74 
CHI=33.4, 4df 
P<0.001 
 
Table 2: Observed versus expected distribution of tumours with strongly 
methylated promoters 
  CYGB      
RARß 0.46* RARß     
CCNA1 0.13 0.15 CCNA1    
p16 0.16 0.29 0.13 p16   
MGMT 0.24 0.28 0.35* 0.12 MGMT  
CDH1 -0.22 0.01 0.28 -0.03 0.27 CDH1 
TIMP3 -0.05 -0.01 0.26 0.09 0.08 0.21 
 
Table 3: Spearman correlations between high levels of promoter 
methylation of individual gene 
CYGB: cytoglobin; CCNA1: cyclin A1; CDH1: E-cadherin 
 P<0.01 
 
 
Anneroth 
Score 
Number of cases 
Strongly 
methylated 
Weakly 
methylated 
8 1 0 
11 2 1 
12 2 1 
13 2 1 
14 1 1 
15 1 0 
16 2 3 
17 0 2 
18 0 1 
19 1 0 
 
Table 4: Anneroth score in methylation subgroups 
 
 
 
 
Reference List 
 
 (1)  Fan CY. Epigenetic alterations in head and neck cancer: prevalence, 
clinical significance, and implications. Curr Oncol Rep 2004; 
6(2):152-161. 
 (2)  Shaw R. The epigenetics of oral cancer. Int J Oral Maxillofac Surg 
2006; 35(2):101-108. 
 (3)  Ha PK, Califano JA. Promoter methylation and inactivation of 
tumour-suppressor genes in oral squamous-cell carcinoma. Lancet 
Oncol 2006; 7(1):77-82. 
 (4)  Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ et al. 
Cancer epigenetics and methylation. Science 2002; 297(5588):1807-
1808. 
 (5)  Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell 
Physiol 2000; 183(2):145-154. 
 (6)  Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 
Methylation-specific PCR: a novel PCR assay for methylation status 
of CpG islands. Proc Natl Acad Sci U S A 1996; 93(18):9821-9826. 
 (7)  Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA 
methylation assay. Nucleic Acids Res 1997; 25:2532-2534. 
 (8)  Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative 
analysis of aberrant p16 methylation using real-time quantitative 
methylation-specific polymerase chain reaction. Cancer Res 1999; 
59(16):3899-3903. 
 (9)  Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D et 
al. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and 
cytoglobin in oral cancer: quantitative evaluation using 
pyrosequencing. Br J Cancer 2006; 94(4):561-568. 
 (10)  Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and 
quantitative universal Pyrosequencing methylation analysis of CpG 
sites. Biotechniques 2003; 35(1):146-150. 
 (11)  Kimura N, Nagasaka T, Murakami H, et al. Methylation profiles of 
genes utilising newly developed CpG island microarray on colorectal 
cancer patients. Nucleic Acids Res 2005; 33(5):e46. 
 (12)  Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. 
CpG island methylator phenotype in colorectal cancer. Proc Natl 
Acad Sci U S A 1999; 96(15):8681-8686. 
 (13)  Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K et al. 
Aberrant methylation in gastric cancer associated with the CpG 
island methylator phenotype. Cancer Res 1999; 59(21):5438-5442. 
 (14)  Kinzler KW, Vogelstein B. Lessons from hereditory colorectal cancer. 
Cell 1996; 87:159-170. 
 (15)  Anacleto C, Leopoldino AM, Rossi B, Soares FA, Lopes A, Rocha JC 
et al. Colorectal cancer "methylator phenotype": fact or artifact? 
Neoplasia 2005; 7(4):331-335. 
 (16)  Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El Naggar AK et al. A 
novel C/T polymorphism in the core promoter of human de novo 
cytosine DNA methyltransferase 3B6 is associated with prognosis in 
head and neck cancer. Int J Oncol 2004; 25(4):993-999. 
 (17)  Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger 
A, Torres A. Lack of CpG island methylator phenotype defines a 
clinical subtype of T-cell acute lymphoblastic leukemia associated 
with good prognosis. J Clin Oncol 2005; 23(28):7043-7049. 
 (18)  Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling 
of twenty four genes and the concordant methylation behaviours of 
nineteen genes that may contribute to hepatocellular carcinogenesis. 
Cell Res 2003; 13(5):319-333. 
 (19)  Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y et al. CpG 
island methylator phenotype is a strong determinant of poor 
prognosis in neuroblastomas. Cancer Res 2005; 65(3):828-834. 
 (20)  Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, 
Murtaugh MA et al. Evaluation of a large, population-based sample 
supports a CpG island methylator phenotype in colon cancer. 
Gastroenterology 2005; 129(3):837-845. 
 (21)  Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K et al. 
Analysis of molecular alterations in left- and right-sided colorectal 
carcinomas reveals distinct pathways of carcinogenesis: proposal 
for new molecular profile of colorectal carcinomas. J Mol Diagn 2006; 
8(2):193-201. 
 (22)  Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG et al. Epstein-
barr virus-positive gastric carcinoma demonstrates frequent aberrant 
methylation of multiple genes and constitutes CpG island methylator 
phenotype-positive gastric carcinoma. Am J Pathol 2002; 160(3):787-
794. 
 (23)  Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M et al. 
Genetic, epigenetic, and clinicopathologic features of gastric 
carcinomas with the CpG island methylator phenotype and an 
association with Epstein-Barr virus. Cancer 2006; 106(7):1467-1479. 
 (24)  Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005; 
129(3):1121-1124. 
 (25)  Auerkari EI. Methylation of tumor suppressor genes p16(INK4a), 
p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 2006; 
42(1):5-13. 
 (26)  Kulkarni V, Saranath D. Concurrent hypermethylation of multiple 
regulatory genes in chewing tobacco associated oral squamous cell 
carcinomas and adjacent normal tissues. Oral Oncol 2004; 40(2):145-
153. 
 (27)  Piyathilake CJ, Bell WC, Jones J, Henao OL, Heimburger DC, 
Niveleau A et al. Pattern of nonspecific (or global) DNA methylation 
in oral carcinogenesis. Head Neck 2005; 27(12):1061-1067. 
 (28)  Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, 
Weisenberger DJ et al. CpG island methylator phenotype (CIMP) of 
colorectal cancer is best characterized by quantitative DNA 
methylation analysis and prospective cohort studies. Gut 2006. 
 (29)  Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y et al. 
Inverse correlation between cyclin A1 hypermethylation and p53 
mutation in head and neck cancer identified by reversal of epigenetic 
silencing. Cancer Res 2004; 64(17):5982-5987. 
 (30)  Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME et 
al. The ATM/p53 pathway is commonly targeted for inactivation in 
squamous cell carcinoma of the head and neck (SCCHN) by multiple 
molecular mechanisms. Oral Oncol 2005; 41(10):1013-1020. 
 (31)  Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a 
small region of the hMLH1 promoter invariably correlates with the 
absence of gene expression. Cancer Res 1999; 59(9):2029-2033. 
 (32)  Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP et al. O6-
methylguanine-DNA methyltransferase gene: epigenetic silencing 
and prognostic value in head and neck squamous cell carcinoma. 
Cancer Epidemiol Biomarkers Prev 2004; 13(6):967-975. 
 (33)  Youssef EM, Issa JP, Lotan R. Regulation of RARbeta1 expression in 
head and neck cancer cells by cell density-dependent chromatin 
remodeling. Cancer Biol Ther 2004; 3(10):1002-1006. 
 (34)  Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L et al. 
Hypermethylation of the retinoic acid receptor-beta(2) gene in head 
and neck carcinogenesis. Clin Cancer Res 2004; 10(5):1733-1742. 
 (35)  Yeh KT, Shih MC, Lin TH, Chen JC, Chang JY, Kao CF et al. The 
correlation between CpG methylation on promoter and protein 
expression of E-cadherin in oral squamous cell carcinoma. 
Anticancer Res 2002; 22(6C):3971-3975. 
 (36)  Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR et al. 
Decreased STAT1 expression by promoter methylation in squamous 
cell carcinogenesis. J Natl Cancer Inst 2006; 98(3):181-189. 
 (37)  Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. 
Methylation of APC, TIMP3, and TERT: a new predictive marker to 
distinguish Barrett's oesophagus patients at risk for malignant 
transformation. J Pathol 2006; 208(1):100-107. 
 (38)  McRonald FE, Liloglou T, Xinarianos G, Hill L, Rowbottom L, Langan 
JE et al. Down-regulation of the cytoglobin gene, located on 17q25, 
in tylosis with oesophageal cancer (TOC): evidence for trans-allele 
repression. Hum Mol Genet 2006; 15(8):1271-1277. 
 (39)  Shahabi M, Noori Daloii MR, Langan JE, Rowbottom L, Jahanzad E, 
Khoshbin E et al. An investigation of the tylosis with oesophageal 
cancer (TOC) locus in Iranian patients with oesophageal squamous 
cell carcinoma. Int J Oncol 2004; 25(2):389-395. 
 (40)  Risk JM, Evans KE, Jones J, Langan JE, Rowbottom L, McRonald FE 
et al. Characterization of a 500 kb region on 17q25 and the exclusion 
of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) 
locus. Oncogene 2002; 21(41):6395-6402. 
 (41)  Liloglou T, Maloney P, Xinarianos G, Fear S, Field JK. Sensitivity and 
limitations of high throughput fluorescent microsatellite analysis for 
the detection of allelic imbalance: application in lung tumors. Int J 
Oncol 2000; 16(1):5-14. 
 (42)  Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney 
JR et al. Cancer-specific genomic instability in bronchial lavage: a 
molecular tool for lung cancer detection. Cancer Res 2001; 
61(4):1624-1628. 
 
 (43)  Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban 
PR et al. Overexpression of aurora B kinase (AURKB) in primary non-
small cell lung carcinoma is frequent, generally driven from one 
allele, and correlates with the level of genetic instability. Br J Cancer 
2005; 93(6):719-729. 
(44)  Woolgar JA, Scott J. Prediction of cervical lymph node metastasis in 
squamous cell carcinoma of the tongue/floor of mouth. Head Neck 
1995;17(6):463–72.  
(45) Rogers SN, Beirne JC, Patel M, Vaughan ED, Brown JS. A clinician 
friendly computerised head and neck oncology audit: the first year 
results. Ann R Coll Surg Engl 1996; 78(1 Suppl):14-18. 
(46)  Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. 
Selectively advantageous mutations and hitchhikers in neoplasms: 
p16 lesions are selected in Barrett’s esophagus. Cancer Res 
2004;64(10):3414–27. 
 (47)  Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking 
microbial infections to chronic inflammation and cancer. Cell 2006; 
124(4):823-835. 
 (48)  Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a 
mechanism for early oncogenic pathway addiction? Nat Rev Cancer 
2006; 6(2):107-116. 
 (49)  House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH et 
al. Progression of gene hypermethylation in gallstone disease 
leading to gallbladder cancer. Ann Surg Oncol 2003; 10(8):882-889. 
 (50)  Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y et al. 
Hypermethylation of the p14(ARF) gene in ulcerative colitis-
associated colorectal carcinogenesis. Cancer Res 2002; 62(4):1148-
1151. 
 (51)  Samowitz WS, Albertson H, Herrick J, et al. Evaluation of a large, 
population-based sample supports a CpG Island Methylator 
Phenotype in Colon Cancer. Gastroenterology 2005; 129:837-845. 
 (52)  Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG 
island hypermethylation of chronic gastritis, in relation to aging, 
gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 
2003; 163(4):1551-1556. 
 (53)  Blackburn TK, Bakhtawar S, Brown JS, Lowe D, Vaughan ED, Rogers 
SN. A questionnaire survey of current UK practice for adjuvant 
radiotherapy following surgery for oral and oropharyngeal squamous 
cell carcinoma. Oral Oncol 2006. 
 
(54)  O’Brien CJ, Lauer CS, Fredricks S, Clifford AR, McNeil EB, Bagia JS, 
et al. Tumor thickness influences prognosis of T1 and T2 oral cavity 
cancer – but what thickness? Head Neck 2003;25(11):937–45. 
 
(55)  Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical 
lymph node metastasis in oral cancer: the importance of even 
microscopic extracapsular spread. Oral Oncol 2003;39(2): 130–7. 
 
 
 
 
Figure 1 Photomicrograph demonstrating characteristics of deep invasive front 
(H&E ·20) of CIMP+ve tumour with profound inflammatory infiltrate. This SCC 
maxilla had pTNM staging: T4N0M0, with a depth of invasion 12 mm. Notably 
there was strong methylation of CYGB, RARb, cyclin A1 and MGMT. Latest 
clinical information is disease free survival at 25 months. The section shows 
a relatively cohesive advancing tumour front and obvious adjacent band of 
inflammation within underlying muscle. 
 
 
 
Figure 2 Photomicrograph demonstrating characteristics of deep invasive front 
(H&E ·20): CIMP_ve tumour with virtually absent inflammatory response. This 
case is from a tongue SCC pTNM stage T3N1M0 with a depth of invasion 30 
mm. The MtI was below threshold or zero for all tested gene promoters. This 
patient had an aggressive tumour and unfortunately died of disease secondary 
to loco-regional recurrence at 7 months. A rather non-cohesive advancing front is 
seen with tumour cords in a desmoplastic but minimally inflamed stroma. 
